Browsing Tag
Jazz Pharmaceuticals
13 posts
Jazz Pharmaceuticals closes $820m Actio Biosciences deal to deepen epilepsy pipeline
Jazz Pharmaceuticals buys Actio Biosciences for $820 million upfront, betting on ABS-1230 while early-stage clinical risk remains the key test.
Zymeworks gets $250m boost after Ziihera wins major first-line cancer approval
FDA expands Ziihera into first-line HER2-positive gastroesophageal cancer, unlocking $250 million for Zymeworks. See why the approval matters.
Jazz Pharmaceuticals raises $1.1bn at 1.875% while repurchasing $225m of stock
Jazz Pharmaceuticals has priced $1.1 billion of 1.875% exchangeable notes due 2032, generating about $1.08 billion of net proceeds while concurrently repurchasing $225 million of shares.
Ziihera FDA approval unlocks $250m for Zymeworks as Jazz expands HER2 drug into first-line gastric cancer
The FDA has approved two Ziihera-based first-line regimens for HER2-positive advanced gastroesophageal adenocarcinoma, triggering a $250 million payment to Zymeworks and giving Jazz a much larger commercial opportunity.
Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR
Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk.
BeOne Medicines wins FDA Priority Review for TEVIMBRA in HER2-positive GEA as ONC stock faces trial-to-approval test
BeOne has survival data and FDA momentum. The bigger question is whether TEVIMBRA can change first-line HER2-positive GEA care.
Lilly bets $7.8bn on orexin science with Centessa acquisition as neuroscience race intensifies
Eli Lilly agrees to acquire Centessa Pharmaceuticals for $6.3B, gaining orexin sleep drug cleminorexton. Read the full strategic analysis.
U.S. stock market selloff: Alphabet, Sarepta, Lantheus lead broad decline amid trade tensions and economic headwinds
See why top U.S. stocks including Alphabet, Sarepta, Lantheus, and Marvell tumbled on May 7 amid rising trade tensions and economic uncertainty.
Jazz Pharmaceuticals’ zanidatamab shows promising results in HER2-positive biliary tract cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing…
Jazz Pharmaceuticals to acquire Redx Pharma’s KRAS inhibitor program to expand oncology pipeline
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) have entered into a definitive agreement, marking…